Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pimitespib’s likelihood of approval (LoA) and phase transition for Metastatic Biliary Tract Cancer took place on 08 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 08 Sep 2022 decreased Pimitespib’s Phase Transition Success Rate (PTSR) for Metastatic Lung Cancer, decreased PTSR for Metastatic Pancreatic Cancer, and decreased LoA and PTSR for Solid Tumor.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pimitespib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pimitespib overview

Pimitespib (Jeselhy) belongs to a class of antineoplastic drugs. It is formulated as tablets for oral route of administration. Jeselhy is indicated for the treatment of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.

Pimitespib (TAS-116) is under development for the treatment of solid tumors including  metastatic pancreatic cancer, metastatic biliary tract cancer, metastatic lung cancer, HER2 negative breast cancer, small cell lung cancer, endometrial cancer, bladder cancer and non-small cell lung carcinoma. It is a small molecule administered orally. It is a HSP90 inhibitor.

It was under development for gastric cancer,HER2+ breast cancer, thymic carcinoma and solid tumor

Otsuka Pharmaceutical overview

Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. It’s nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.

Quick View Pimitespib LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Pimitespib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.